The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat …

Objective To compare the effects of treatments for coronavirus disease 2019 (covid-19).
Design Living systematic review and network meta-analysis. Data sources WHO covid-19 …

Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-
19 antiviral treatments, but their antiviral activities in patients have not been compared …

Summary Introduction Continued SARS-CoV-2 infection among immunocompromised
individuals is likely to play a role in generating genomic diversity and the emergence of …

Background. Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) were recently approved for
the early treatment of COVID-19, but real-life data on tolerability, safety, and adverse events …

Abstract Molnupiravir, EIDD-2801/MK-4482, the prodrug of the ribonucleoside analog ß-d-
N4-hydroxycytidine (NHC), has activity against a number of RNA viruses including severe …

Molnupiravir is a β-d-N4-hydroxycytidine-5′-isopropyl ester (NHC) compound that exerts
antiviral activity against various RNA viruses such as influenza, SARS, and Ebola viruses …

At a crucial time with rapid spread of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) Omicron variant globally, the United States Food and Drug Administration …

Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for
patients with the 2019 coronavirus (COVID-19). However, little is known about their …

Background: Molnupiravir demonstrated an in vitro antiviral activity against positive-sense
RNA viruses, including SARS-CoV-2. The study aimed to present the results of outpatient …